Nasdaq
$4.60▼ 0.43%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $18.6MShares out 4.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.6After-hours26.10.07 07:064Ownership#●●●
KYNTRA BIO, INC.
Kyntra Bio, Inc. insider Andrew E. Singer filed a Form 4 report regarding changes in beneficial ownership of securities as of October 1, 2026. This filing serves as a disclosure of executive stock holdings and does not contain information regarding changes to the company's capital structure or financial position.…more
$4.60-0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 07:043Ownership
KYNTRA BIO, INC.
Andrew Singer of Kyntra Bio, Inc. has filed a limited power of attorney to authorize company personnel and legal counsel to fulfill reporting obligations under Section 16 of the Securities Exchange Act. This action grants these designated individuals the legal authority to prepare and file Forms 3, 4, and 5 with the SEC on behalf of Mr. Singer.…more
$4.60-0.43%vs prev closeView filingShare - 10.6After-hours26.10.07 05:058-KKey event
KYNTRA BIO, INC.
Kyntra Bio, Inc. has received a delisting determination from Nasdaq for failing to comply with Listing Rule 5450(b). The company has requested a hearing before a Nasdaq Hearings Panel to appeal the decision, allowing its common stock to remain listed and trade on the Nasdaq Global Select Market pending the panel's final decision.…more
$4.60-0.43%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 20:00#●●●#●●●
Kyntra Bio Appoints Andrew E. Singer to Board of Directors
Kyntra Bio has appointed biotechnology finance expert Andrew E. Singer as an independent director to its board. This leadership change is intended to support the company's strategic priorities, though it has no immediate impact on stock performance.…more
$4.60-0.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.2Pre-market26.09.02 20:30
●●●●●●●● ●●●●● ●●●●●●
Kyntra Bio announced that its management will participate and present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The company will also hold one-on-one meetings with investors to discuss its business developments.…more
$4.60-0.43%vs prev close - 8.31After-hours26.09.01 05:10
●●●●●●●● ●●●●● ●●●●●●
Kyntra Bio has amended its royalty financing agreement, reducing the maximum aggregate payment obligations from $125 million to $65 million. This restructuring improves the company's balance sheet and extends its cash runway through the fourth quarter of 2027.…more
$4.60-0.43%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report